Bristol Myers Squibb Acquires Cell Therapy Portfolio with Acquisition of Orbital Therapeutics for $1.5 billion in cash
On Oct. 10, 2025, Bristol Myers Squibb (BMS) and Orbital Therapeutics announced a definitive agreement under which BMS…
-
-
U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast) tablets as first new treatment option for adults with IPF in over a decade
On Oct. 9, 2025, Boehringer Ingelheim’s JASCAYD® (nerandomilast) tablets has been approved by the U.S. Food and Drug…
-
Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)
On Oct. 9, 2025, Celltrion announced announced that the U.S. Food and Drug Administration (FDA) has approved EYDENZELT® (aflibercept-boav), biosimilar…
-
Biotechnology | Clinical Research | Infectious Disease | Medical Device | Therapeutics | Vaccine | WHO
WHO launches the Global Clinical Trials Forum
On Oct. 7, 2025, the World Health Organization (WHO) launched the Global Clinical Trials Forum (GCTF), a global,…
-
Texas Children’s/Baylor researchers developed new tool to improve accuracy of genetic testing
On Oct. 7, 2025, researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research…
-
Bath scientists design peptide ‘switch’ that keeps Parkinson’s protein in its healthy form
On Oct. 6, 2025, Researchers at the University of Bath, in collaboration with the Universities of Oxford and…
-
the 2025 Nobel Prize in Physiology or Medicine awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance”
On Oct. 6, 2025, The Nobel Assembly has awarded the Nobel Prize in Physiology or Medicine to Mary E. Brunkow, Fred…
-
FDA Announces New ANDA Prioritization Pilot to Support U.S. Generic Drug Manufacturing and Testing
On Oct. 3, 2025, the U.S. Food and Drug Administration (FDA) announced a new pilot prioritization program for…
-
South Carolina Department of Public Health Confirms Measles Outbreak
On Oct. 2, 2025, the South Carolina Department of Public Health (DPH) has confirms a measles outbreak in…
-
FDA approved Evita Solution’s generic version of the abortion drug, mifepristone
On Oct. 2, 2025, the U.S. Food and Drug Administration (FDA) approved Evita Solution’s generic version of the…
-
Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients
On Sept. 30, 2025, Pfizer announced an agreement with the White House that will ensure U.S. patients pay…
-
Solid dose vaccine protects pigs against virus
On Sept. 30, 2025, a team of researchers involving Roslin Institute scientists tested a solid dose of a…
-
Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US
On Sept. 26, 2025, Sanofi US announced a broad expansion of its Insulins Valyou Savings Program by offering…
-
Amgen Announces $650 Million Manufacturing Expansion in Puerto Rico
On Sept. 26, 2025, Amgen announced a $650 million expansion of its U.S. manufacturing network in Puerto Rico,…
-
CIRM approves $73 million in awards for discovery research
On Sept. 25, 2025, The California Institute for Regenerative Medicine (CIRM) has approved awarding more than $73 million…
-
Final Landmark Clinical Trial Data Demonstrates Deep, Durable Responses to Menin Inhibition in Acute Leukemia Patients
On Sept. 25, 2025, Final data from a landmark clinical trial in patients with an aggressive form of…
-
Gene therapy appears to slow Huntington’s disease progression
On Sept. 24, 2025, a global clinical trial for a new Huntington’s disease treatment has posted positive results,…
-
Variational AI Enters $349 Million Collaboration with Merck to Apply Generative AI to Drug Discovery
On Sept. 23, 2025, Variational AI a generative AI drug discovery company, announced a collaboration with Merck to…
-
Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio for $4.9 billion
On Sept. 22, 2025, Pfizer and Metsera announced the companies have entered into a definitive agreement under which…
-
Biogen to Acquire Alcyone Therapeutics for $85 million, Expanding Drug Delivery Solution Portfolio
On Sept. 18, 2025, Biogen announced it has has entered into a definitive agreement to acquire Massachusetts-based Alcyone…
-
Biogen Receives EC Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
On Sept. 17, 2025, Biogen announced that the European Commission (EC) has granted marketing authorization for ZURZUVAE® (zuranolone)…
-
Roche to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH for US $3.5 billion
On Sept. 17, 2025, Roche announced that it has entered into a definitive merger agreement to acquire 89bio,…
-
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill) delivered 16.6% weight loss in people with obesity in a newly published study
On Sept. 17, 2025, The New England Journal of Medicine published the results from the OASIS 4 phase…
-
Lilly announces plans to build $5 billion manufacturing facility in Virginia
On Sept. 16, 2025, Eli Lilly announced that it plans to build a $5 billion manufacturing facility just…
-
New University of Alberta health institute will help research breakthroughs reach patients sooner
On Sept. 15, 2025, the University of Alberta (U of A) announced the Dianne and Irving Kipnes Health…
-
Biotechnology | Disease | FDA | Therapeutics
Corstasis Therapeutics Announces FDA Approval of ENBUMYST™ (bumetanide nasal spray) for the Treatment of Edema Associated with Congestive Heart Failure, Liver Disease and Kidney Disease
On Sept. 15, 2025, Corstasis Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved ENBUMYST™…
-
gene therapy offers hope for genetic hearing loss
On Sept. 14, 2025, scientists from the Gray Faculty of Medical & Health Sciences at Tel Aviv University…
-
3D bioprinted mini placentas could transform pregnancy research
On Sept. 12, 2025, scientists from the University of Technology Sydney (UTS) announced they have achieved a major…
-
Melinda French Gates launches $100 million push for women’s health research
On Sept. 10, 2025, philanthropist Melinda French Gates announces she will invest $50 million in a women’s health…
-
Merck to scrap London drug research centre
On Sept. 10, 2025, Merck announced it was scrapping research operations in London, citing the UK’s challenging business…
